P. R. Lowenstein

This paper models glioma oncostreams in vitro, showing their formation, stability, and response to pharmacological agents, with insights into potential anti-invasion targets.

This study identifies de novo lipogenesis as a vulnerability in IDH1 mutant gliomas, showing that HDAC inhibition and FASN targeting reduce tumor growth and improve survival.

This paper identifies ZMYND8 as a gene epigenetically regulated by mIDH1 that promotes radioresistance in glioma cells, and shows its knockdown enhances radiosensitivity.

This paper develops synthetic protein nanoparticles delivering a CXCR4 inhibitor to treat glioma by enhancing immunotherapy and reducing tumor progression.

The paper shows radiation induces vascular-like phenotypes in glioma stem cells, creating a trophic niche that promotes tumor recurrence, and identifies P300 inhibition as a potential therapeutic strategy.

The paper identifies COL1A1 as a key driver of glioma mesenchymal differentiation and invasion, showing its inhibition disrupts tumor structure and improves survival.

This study shows that inhibiting 2-hydroxyglutarate in mIDH1 gliomas with ATRX/TP53 inactivation improves survival and induces anti-tumor immunity through immunological memory and reduced T-cell exhaustion.

This study develops synthetic protein nanoparticles for GBM therapy, showing they deliver STAT3i siRNA to tumors, enhance radiation response, and induce immune memory in mice.

This study shows that FYN tyrosine kinase in glioma cells suppresses anti-glioma immune responses, and its inhibition reduces tumor growth and improves survival in immune-competent models.